Background and aim: Hyperinflammatory host response associated with diabetes mellitus significantly provokes periodontal tissue destruction. In this context, supporting the standard treatment of periodontitis in diabetics with host modulation agents is a current field of study. This clinical study aims to investigate the clinical efficacy of melatonin supplementation in non-surgical periodontal treatment in patients with Type 2 DM and periodontitis and its biological basis (clinical effectiveness) based on some basic markers. Material and method: In this randomized controlled and double-blind study, 27 of 55 patients with diabetic periodontitis underwent full mouth scaling and root planning (fmSRP) alone and 28 of them were administered melatonin (6 mg daily, for 30 days) in addition to fmSRP. The possible therapeutic contribution of melatonin was evaluated clinically and biochemically \[gingival crevicular fluid (GCF) RANKL, OPG and MMP-8 and serum IL-1β levels\] at 3 and 6 months.
Age range
31 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Clinical Findings: Plaque index score(PI)
Timeframe: Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Clinical Findings: Gingival index score (GI)
Timeframe: Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Clinical Findings: Bleeding on probing(BOP)
Timeframe: Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Clinical Findings:Probing pocket depth (PPD)
Timeframe: Change from baseline(T0) to 3rd month (T1) and 6th month (T2)
Clinical Findings: Clinical Attachment Level (CAL)
Timeframe: Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Biochemical Findings: RANKL (pg/ml)
Timeframe: Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Biochemical Findings: OPG (pg/ml)
Timeframe: Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Biochemical Findings: MMP-8(ng/ml)
Timeframe: Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Biochemical Findings: IL-beta(pg/ml)
Timeframe: Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Biochemical Findings: RANKL/OPG
Timeframe: Change from baseline(T0) to 3rd month(T1) and 6th month(T2)